Importantly, they underscore the therapeutic potential of oral GUCY2C ligands to prevent or treat diseases reflecting intestinal stem cell dysfunction, including the radiation-induced gastrointestinal syndrome. This evidence concerns the gene GUCY2C and radiation-induced gastrointestinal mucositis.